News coverage about AVEO Pharmaceuticals (NASDAQ:AVEO) has trended somewhat positive recently, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AVEO Pharmaceuticals earned a coverage optimism score of 0.08 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.6999222527481 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern Sentiment’s analysis:
- Ex-Aveo CFO Denied Quick Win In SEC’s Cancer Drug Suit (law360.com)
- AVEO Pharmaceuticals, Inc. (AVEO) Stock Regains Attentions on Moves of SMA (investingbizz.com)
- Stocks Overview: Aveo Pharmaceuticals (AVEO) and Navios Maritime Partners LP (NMM) (postregistrar.com)
- Illiquidity and Stocks: returns: HP Inc. (NYSE:HPQ), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) (thestreetpoint.com)
- Momentum Stocks in Focus- HP Inc. (NYSE:HPQ), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), Waste Management … (journalfinance.net)
AVEO Pharmaceuticals stock opened at $2.64 on Monday. AVEO Pharmaceuticals has a 1-year low of $0.57 and a 1-year high of $4.24. The company has a market capitalization of $307.87, a P/E ratio of -16.50 and a beta of 1.32. The company has a quick ratio of 1.56, a current ratio of 1.56 and a debt-to-equity ratio of -0.45.
In other news, major shareholder Ravi Viswanathan purchased 685,676 shares of AVEO Pharmaceuticals stock in a transaction dated Friday, April 6th. The stock was purchased at an average cost of $2.24 per share, for a total transaction of $1,535,914.24. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Peter J. Barris purchased 920,976 shares of AVEO Pharmaceuticals stock in a transaction dated Tuesday, April 10th. The shares were purchased at an average price of $2.30 per share, with a total value of $2,118,244.80. The disclosure for this purchase can be found here. 4.70% of the stock is currently owned by insiders.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.